Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Jin Mi Kim

René Marc Lemieux

Terence Alfred Kelly

Matt Aaron Tschantz

Peter Allen Nemoto

Michel Jose Emmanuel

Ho Yin Lo

Steven Richard Brunette

Xin Guo

Bryan Patrick McKibben

Kevin Chungeng Qian

Hui Yu

Eugene R Hickey

Ming-Hong Hao

Hidenori Takahashi

Tina Marie Morwick

Stephane De Lombaert

Brian Nicholas Cook

Asitha Abeywardane

Chuk Chui Man

Steven John Taylor

Antonio J M Barbosa

Michael David Lawlor

Rene' Marc Lemieux

Rene′ Marc Lemieux

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

Benzimidazolone chymase inhibitors

Disclosed are small molecule inhibitors of the formula (I): and the pharmaceutical compositions thereof and processes of making the same. The compounds are useful in treating various diseases and conditions involving chymase. 

Aza-benzimidazolone Chymase inhibitors

Disclosed are novel compounds of formula (I): wherein X, Y, R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

[object Object]

The invention comprises a class of derivatives of substituted benzylimidazoles of the formula (I) and methods for making the same. These compounds are useful for the treatment of inflammatory conditions. 

Substituted benzylimidazoles useful for the treatment of inflammatory diseases

Disclosed are novel compounds of formula (I): wherein R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyridine derivatives useful as inhibitors of PKC-theta

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of [6,7-dihydro-5H-imidazol[1,2-a]imidazole-3-sulfonylamino]-propionamide

Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide

Growing community of inventors

Sandy Hook, CT, United States of America

Jin Mi Kim